Regenerative Medicine in Pharma Market to Grow by 11.1% Annually Through 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2022--
The “Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), and Segment Forecast, 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027. The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.
The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.
- Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
- Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
- Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
- Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.
- The competitive landscape: an examination of the positioning of leading players in regenerative medicine in pharma market.
Reasons to Buy
- This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
- Accompanying the publisher’s Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in regenerative medicine in pharma markets.
- The report also highlights key product, therapeutic area segments.
- With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
- The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in regenerative medicine in pharma market.
Key Topics Covered:
CHAPTER 01 Executive Summary
CHAPTER 02 Market Landscape
CHAPTER 03 Regenerative Medicine in Pharma Value Chain
CHAPTER 04 Regulatory and Market Access
4.1 Differences Between Conventional Therapies and Stem Cell Therapies in Clinical Trials
4.2.2 Market Access
4.4 Regulation of Regenerative Medicine in the US and Europe
4.6 South Korea
CHAPTER 05 Marketed Products
5.1.1 Leading Cell-Based Immunotherapy Treatments
5.1.2 Leading Gene Therapy Treatments
5.1.3 Leading Cell-Therapies Treatment
5.1.4 Leading Tissue Engineered Products Treatments
CHAPTER 06 Regenerative Medicine Pipeline Products in the 8MM
6.1 Late-Stage Gene Therapy Products
6.2 Late-Stage Gene-Modified Cell Therapy Products
6.3 Late-Stage Cell Therapy Products
6.4 Late-Stage Tissue-Engineered Treatment
CHAPTER 07 Regenerative Medicine in Pharma Industry Analysis
7.1 Regenerative Medicine in Pharma Market Structure - PORTER’s Analysis
7.2 Deals in Regenerative Medicine in Pharma
7.3 Funding in Regenerative Medicine in Pharma
CHAPTER 08 Global Regenerative Medicine in Pharma Revenue Opportunity
8.1 Global Digital Biomarkers Market
8.2 COVID-19 Pandemic
CHAPTER 09 Regenerative Medicine in Pharma Product Outlook
9.1 Regenerative Medicine in Pharma - Product Dive
9.1.1 Tissue-Engineered Products
9.1.2 Gene Therapies
9.1.3 Cell Therapies
CHAPTER 010 Regenerative Medicine in Pharma Therapeutic Area Outlook
10.1 Regenerative Medicine in Pharma - Therapeutic Area Dive
CHAPTER 011 Regenerative Medicine in Pharma Regional Outlook
11.1 Regenerative Medicine in Pharma - Regional Deep Dive
11.1.1 North America
CHAPTER 012 Trends, Drivers, and Challenges
12.1 Regenerative Medicine in Pharma - Market Trends
12.1.1 Constant Innovation in Cell Engineering Techniques:
12.1.2 Increasing Application of Gene Therapy:
12.1.3 Fast Track Approvals and Multiple Drugs in Last Stages of Pipeline
12.1.4 the Momentum Created by Allogenic Therapeutics Continues to Drive Market:
12.1.5 Increasing Applications of 3D Printing in Regenerative Medicine:
12.2 Regenerative Medicine in Pharma - Market Drivers
12.2.1 Growing Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
12.2.2 Technological Advancements in Stem-Cell Therapies
12.2.3 Increased Investment by Key Players in R&D of the Regenerative Medicines
12.3 Regenerative Medicine in Pharma - Market Challenges
12.3.1 Gene Therapy
12.3.2 Cell Therapy
12.3.3 Tissue-Engineered Products and Biomaterials
CHAPTER 013 Regenerative Medicine in Pharma Market Vendor Snapshot
CHAPTER 014 Appendix
- Bristol Myers-Squibb
- Bluebird bio
- Johnson & Johnson
- PTC Therapeutics
- Orchard Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/47qzh8
View source version on businesswire.com:https://www.businesswire.com/news/home/20221219005338/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 12/19/2022 05:12 AM/DISC: 12/19/2022 05:12 AM